Dialog Box

Loading...

Some of the new therapies for lymphoma and CLL

IBRUTINIB

Ibrutinib also known as PCI-32765 and marketed under the name Imbruvica is currently TGA registered in Australia and available in clinical trials for some subtypes. Ibrutinib is a cell signal blocker that targets Bruton’s tyrosine kinase (BTK). BTK is a part of a pathway that helps B cells to stay alive and divide. Blocking BTK promotes death of B cells, including lymphoma cells that develop from B cells, and prevents their division. This stops the spread of lymphoma cells.

Ibrutinib is given as capsules. It is taken orally (by mouth) and your recommended dose of ibrutinib is based on the type of lymphoma you have and your general health. Clinical trials are currently testing whether ibrutinib could help people with the following types of lymphoma: either on its own or in combination with other treatments, such as chemotherapy or antibody therapy, eg rituximab

  • Mantle Cell lymphoma
  • Follicular Lymphoma
  • Chronic Lymphocytic Leukemia
  • Waldenstroms Lymphoma
  • Marginal zone lymphoma
  • Diffuse Large B Cell (particularly subtypes called non-GCB type).
Some patients may be able to enroll in a clinical trial testing ibrutinib. Ask your doctor if there are any clinical trials suitable for you.

IMBRUVICA (Ibrutinib) is now indicated for the treatment of:

  • Adult patients with CLL/SLL who have received at least one prior therapy, or adult patients with previously untreated CLL/SLL

  • Patients with CLL/SLL with deletion 17p

  • Patients with MCL who have received at least one prior therapy

  • Adult patients with Waldenstrom's macroglobulinaemia (WM) who have received at least one prior therapy, or in first-line treatment for patients unsuitable for combination chemo-immunotherapy

"At 72 years of age I can still ride over 300kms in Parliament2Opera and take 2 Ibrutinib tablets each day", Michael